공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

CAR-T 세포치료 시장 리뷰

CAR-T Cell Therapy Market Review

리서치사 Kalorama Information
발행일 2019년 12월 상품 코드 922775
페이지 정보 영문 59 Pages
가격
US $ 4,000 ₩ 4,452,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF파일의 Copy & Paste 기능은 물리적으로는 가능하나, 리서치사에서는 이를 허용하고 있지 않습니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,678,000 PDF (Departmental Site License - 1 Location, 10 Users)
US $ 8,000 ₩ 8,904,000 PDF (Global Site License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 단, 모회사, 자회사, 관련 회사는 포함되지 않습니다. PDF파일의 Copy & Paste 기능은 물리적으로는 가능하나, 리서치사에서는 이를 허용하고 있지 않습니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


CAR-T 세포치료 시장 리뷰 CAR-T Cell Therapy Market Review
발행일 : 2019년 12월 페이지 정보 : 영문 59 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

CAR-T 세포치료는 암 세포를 표적으로 하고 파괴하기 위해 신체의 T세포를 이용하는 면역치료의 일종입니다. 이 치료법은 맞춤형 치료법이며, 각 환자는 암 진단에 특화된 T 세포를 받습니다. T 세포치료는 환자로부터 기존의 T 세포를 제거하고, 그것을 실험실에서 성장 및 개변시킴으로써 기능합니다. 이러한 새로운 T 세포에는 키메라 항원 수용체(CAR)로서 알려진 특수한 수용체의 유전자가 수여되며, 세포가 암 세포를 특정적으로 공격할 수 있도록 합니다. CAR-T 세포치료는 특히 급성 림프구성 백혈병(ALL), DLBCL B 세포 림프종, 다발성 골수종 질환에서 암 세포 제거에 유효성을 나타내고 있습니다.

CAR-T 세포치료(CAR-T Cell Therapy) 시장에 대해 조사했으며, 시장 동향, 과제 및 최근 발전 동향 등에 대해 분석했습니다.

제1장 주요 요약

제2장 CAR-T 세포치료 시장

  • FDA 승인 CAR-T 요법 : YESCARTA 및 KYMRIAH
  • CAR-T 세포치료 시장 동향/과제
  • 최근의 시장 개발
  • 개발중인 주요 CAR-T 요법
  • CAR-T 시장 분석

제3장 시장 진출 기업

  • ABBVIE, INC.
  • AUTOLUS THERAPEUTICS PLC
  • BELLICUM PHARMACEUTICALS, INC.
  • BLUEBIRD BIO, INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • CARSGEN THERAPEUTICS
  • CELGENE CORPORATION
  • CELLECTIS, INC.
  • CELYAD
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE
  • GRACELL BIOTECHNOLOGY
  • IMMUNE THERAPEUTICS
  • INNOVATIVE CELLULAR THERAPEUTICS
  • JUNO THERAPEUTICS
  • KITE PHARMA, INC.
  • MUSTANG BIO
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC.
  • SORRENTO THERAPEUTICS
  • ZIOPHARM ONCOLOGY,INC
KSM 20.01.31

CAR-T cell therapy is a form of immunotherapy that utilizes the body's own T cells to target and destroy cancer cells. This therapy is a personalized form of treatment, meaning that each patient receives T cells that are geared specifically toward his or her cancer diagnosis. T-cell therapy works by removing existing T cells from a patient and having them grown and modified in a lab. These new T cells are given a gene for a specialized receptor, known as a chimeric antigen receptor (CAR), which allows the cells to specifically attack cancer cells. CAR-T cell therapy has shown effectiveness in eliminating cancer cells, especially for the following diseases:

  • Acute lymphoblastic leukemia (ALL)
  • DLBCL B-cell lymphomas
  • Multiple myeloma

‘CAR-T Cell Therapy Market Review’ discusses CAR-T's impressive revenue growth, which is expected to continue given the effectiveness of the therapy and the projected new users. There are positive factors for the market, though there are limits to growth. Patient volume should increase, though it is likely that the unusually large prices will not sustain over the next five years. The report provides the following market data:

  • CAR-T Market, 2018-2024 ($millions)
  • CAR-T Market Share, 2019 (%)
  • CAR-T Market Regional Breakout, 2019 (%)

‘CAR-T Cell Therapy Market Review’ discusses CAR-T therapy market trends, issues, and recent developments, including the following:

  • Global Cancer Burden
  • Complexity of the CARs Manufacturing Process
  • Diseases Treated with CAR-T
  • Study Shows Yescarta Increases Longevity
  • CRS and Other Side Effects
  • China CAR-T Competition
  • Indian CAR-T Competition
  • "Off-the-Shelf" CAR-T Therapies in Development
  • Competing Therapy in Development

Also noted in the report are selected CAR-T therapies in development, an effort to capture current media coverage of CAR-T trials.

‘CAR-T Cell Therapy Market Review’ notes the activities of many of the major players in the market. The market companies that are covered in the report are the following:

  • AbbVie, Inc.
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellectis, Inc.
  • Celyad
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Immune Therapeutics
  • Innovative Cellular Therapeutics
  • Juno Therapeutics
  • Kite Pharma, Inc.
  • Mustang Bio
  • Novartis International AG
  • Pfizer, Inc.
  • Sorrento Therapeutics
  • ZIOPHARM Oncology, Inc.

Table of Contents

1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • CAR-T THERAPY MARKET TRENDS, ISSUES, AND RECENT DEVELOPMENTS
  • CAR-T THERAPY MARKET
  • COMPANIES IN THE MARKET

2: CAR-T CELL THERAPY MARKET

  • FDA-APPROVED CAR-T THERAPIES: YESCARTA AND KYMRIAH
    • Yescarta
    • Kymriah
      • Table 2-1: FDA-Approved CAR-T Therapies
  • CAR-T THERAPY MARKET TRENDS / ISSUES
    • Global Cancer Burden
      • Figure 2-1: Global Cancer Incidence Trends, 2010-2040
    • Complexity of the CARs Manufacturing Process
    • Diseases Treated with CAR-T
  • RECENT MARKET DEVELOPMENTS
    • Study Shows Yescarta Increases Longevity
    • CRS and Other Side Effects
    • China CAR-T Competition
    • Indian CAR-T Competition
    • "Off-the-Shelf" CAR-T Therapies in Development
  • A Competing Therapy in Development
  • SELECTED CAR-T THERAPIES IN DEVELOPMENT
    • Table 2-2: Selected CAR-T Therapies in Development
  • KTE-X19
  • liso-cel
  • C-CAR088
  • IBI326 (Innovent) / CT103A (IASO BIO)
  • bb21217
  • MB-107
  • ICTCAR014
  • bb2121
  • JNJ-682284528 (JNJ-4528)
  • CT053
  • MB-101 (IL-13Rα2)
  • MB-108 (oncolytic virus C134)
  • CYAD-01
  • BAFF-R CAR-T
  • MB-105 (PSCA)
  • MB-102 (CD123)
  • MB-103 (HER2)
  • P-BCMA-101
  • LCAR-B38M
  • JCARH125
  • MCARH171
  • CYAD-101
  • MB-106 (CD20)
  • MB-104 (CS1)
  • AMG 119
  • ATA2271
  • AUTO1
  • AUTO3
  • CAR-T MARKET ANALYSIS
    • Figure 2-2: CAR-T Market, 2018-2024 ($millions)
    • Market Share
      • Figure 2-3: CAR-T Market Share, 2019 (%)
    • Regional Breakout
      • Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)

3: COMPANIES IN THE MARKET

  • ABBVIE, INC.
    • Company Summary
    • Scripps Research Institute Deal
    • Tyrosine Kinase Inhibitors Market
  • AUTOLUS THERAPEUTICS PLC
  • BELLICUM PHARMACEUTICALS, INC.
  • BLUEBIRD BIO, INC.
    • Company Summary
    • bb2121
    • bb21217
    • bb2121
  • BRISTOL-MYERS SQUIBB COMPANY
    • Company Summary
    • BMS Acquires Celgene
    • Monoclonal Antibodies Market
    • Cancer Kinase Inhibitor Market
  • CARSGEN THERAPEUTICS
  • CELGENE CORPORATION
    • Company Summary
    • Collaboration with Immatics Biotechnologies
    • Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
    • Celgene Buys JAK2 Inhibitor Maker
  • CELLECTIS, INC.
    • Pfizer
    • Servier
  • CELYAD
    • CYAD-01
    • CYAD-101
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE
  • GRACELL BIOTECHNOLOGY
  • IMMUNE THERAPEUTICS
    • CAR-T
  • INNOVATIVE CELLULAR THERAPEUTICS
    • ICTCAR014
  • JUNO THERAPEUTICS
    • Selected CAR-T Therapies in Development
    • Collaboration with Editas Medicine
  • KITE PHARMA, INC.
    • KTE-X19
    • Yescarta
  • MUSTANG BIO
  • NOVARTIS INTERNATIONAL AG
    • Company Summary
    • Kymriah
    • Intellia Therapeutics
    • Other Company Activity
  • PFIZER, INC.
  • SORRENTO THERAPEUTICS
  • ZIOPHARM ONCOLOGY, INC
Back to Top
전화 문의
F A Q